Vera Therapeutics Stock Net Income
| VERA Stock | USD 27.70 0.36 1.32% |
Vera Therapeutics fundamentals help investors to digest information that contributes to Vera Therapeutics' financial success or failures. It also enables traders to predict the movement of Vera Stock. The fundamental analysis module provides a way to measure Vera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vera Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -152.1 M | -144.5 M | |
| Net Income Applicable To Common Shares | 102.4 M | 107.5 M | |
| Net Loss | -152.1 M | -144.5 M | |
| Net Loss | (2.75) | (2.89) | |
| Net Income Per E B T | 1.00 | 1.10 |
Vera | Net Income |
Vera Therapeutics Company Net Income Analysis
Vera Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Vera Therapeutics Net Income | (152.15 M) |
Most of Vera Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vera Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vera Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Vera Therapeutics is extremely important. It helps to project a fair market value of Vera Stock properly, considering its historical fundamentals such as Net Income. Since Vera Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vera Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vera Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Vera Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Vera Therapeutics reported net income of (152.15 Million). This is 144.58% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 126.65% higher than that of the company.
Vera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vera Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vera Therapeutics could also be used in its relative valuation, which is a method of valuing Vera Therapeutics by comparing valuation metrics of similar companies.Vera Therapeutics is currently under evaluation in net income category among its peers.
Vera Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vera Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vera Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Vera Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Vera Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vera Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vera Therapeutics' value.| Shares | Kynam Capital Management, Lp | 2024-12-31 | 1.5 M | Paradigm Biocapital Advisors Lp | 2024-12-31 | 1.4 M | T. Rowe Price Investment Management,inc. | 2024-12-31 | 1.4 M | First Light Asset Management, Llc | 2024-12-31 | 1.3 M | Woodline Partners Lp | 2024-12-31 | 1.2 M | Lord, Abbett & Co Llc | 2024-12-31 | 1.2 M | Geode Capital Management, Llc | 2024-12-31 | 1.2 M | Integral Health Asset Management, Llc | 2024-12-31 | 1.1 M | Federated Hermes Inc | 2024-12-31 | 1.1 M | Venbio Select Advisor Llc | 2024-12-31 | 5.6 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 4.4 M |
Vera Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 1.2 B | ||||
| Shares Outstanding | 63.75 M | ||||
| Shares Owned By Insiders | 7.09 % | ||||
| Shares Owned By Institutions | 92.91 % | ||||
| Number Of Shares Shorted | 8.36 M | ||||
| Price To Earning | 17.01 X | ||||
| Price To Book | 3.10 X | ||||
| EBITDA | (167.17 M) | ||||
| Net Income | (152.15 M) | ||||
| Cash And Equivalents | 131.93 M | ||||
| Cash Per Share | 4.86 X | ||||
| Total Debt | 54.64 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 8.24 X | ||||
| Book Value Per Share | 9.08 X | ||||
| Cash Flow From Operations | (134.68 M) | ||||
| Short Ratio | 7.62 X | ||||
| Earnings Per Share | (2.75) X | ||||
| Target Price | 65.0 | ||||
| Number Of Employees | 112 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 1.79 B | ||||
| Total Asset | 655.68 M | ||||
| Retained Earnings | (461.25 M) | ||||
| Working Capital | 625.85 M | ||||
| Current Asset | 237.64 M | ||||
| Current Liabilities | 54.04 M | ||||
| Net Asset | 655.68 M |
About Vera Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vera Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:Check out Vera Therapeutics Piotroski F Score and Vera Therapeutics Altman Z Score analysis. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.